Equities research analysts expect Clene Inc. (NASDAQ:CLNN – Get Rating) to report ($0.20) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Clene’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.21). Clene reported earnings per share of ($0.21) during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.8%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Clene will report full-year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.67). For the next financial year, analysts forecast that the business will report earnings of $0.02 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Clene.
Clene (NASDAQ:CLNN – Get Rating) last announced its quarterly earnings data on Friday, March 11th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.14 million.
Shares of Clene stock traded up $0.07 during trading on Tuesday, hitting $2.21. 180,009 shares of the company were exchanged, compared to its average volume of 115,684. The firm has a market capitalization of $139.80 million, a P/E ratio of 9.61 and a beta of 0.37. Clene has a 1-year low of $1.93 and a 1-year high of $17.82. The firm’s fifty day moving average price is $2.92 and its 200 day moving average price is $3.59. The company has a debt-to-equity ratio of 9.64, a current ratio of 7.77 and a quick ratio of 7.76.
In other Clene news, Director David J. Matlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 28th. The shares were acquired at an average price of $3.10 per share, for a total transaction of $31,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David J. Matlin purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 18th. The stock was acquired at an average price of $2.79 per share, for a total transaction of $55,800.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 227,891 shares of company stock worth $667,902. Company insiders own 28.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CLNN. State Street Corp grew its holdings in Clene by 126.7% in the 4th quarter. State Street Corp now owns 883,258 shares of the company’s stock valued at $3,621,000 after buying an additional 493,581 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in shares of Clene during the 4th quarter worth $1,106,000. BlackRock Inc. grew its holdings in shares of Clene by 7.5% during the 4th quarter. BlackRock Inc. now owns 1,145,686 shares of the company’s stock worth $4,697,000 after purchasing an additional 79,960 shares in the last quarter. Morgan Jess S & Co. Inc. grew its holdings in shares of Clene by 193.3% during the 1st quarter. Morgan Jess S & Co. Inc. now owns 87,250 shares of the company’s stock worth $344,000 after purchasing an additional 57,500 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Clene during the 4th quarter worth $159,000. 23.07% of the stock is currently owned by hedge funds and other institutional investors.
Clene Company Profile (Get Rating)
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- Get a free copy of the StockNews.com research report on Clene (CLNN)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.